Leading brokers name 3 ASX shares to buy today

Leading brokers have named ResMed Inc. (ASX:RMD) and these ASX shares as shares to buy this week..

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With so many shares to choose from on the Australian share market, it can be hard to decide which ones to buy.

The good news is that brokers across the country are doing a lot of the hard work for you.

Three top shares that leading brokers have named as buys this week are listed below. Here's why they are bullish on them:

a woman

Aristocrat Leisure Limited (ASX: ALL)

According to a note out of Citi, its analysts have retained their buy rating and $39.50 price target on this gaming technology company's shares. The broker appears confident that Aristocrat Leisure is winning market share in the lucrative United States market. This should underpin strong sales and earnings growth in FY 2020. I agree with Citi and feel Aristocrat Leisure is a great option for investors even after its strong gain over the last 12 months.

Praemium Ltd (ASX: PPS)

Analysts at Goldman Sachs have retained their buy rating and lifted the price target on this investment platform provider's shares to 68 cents. According to the note, the broker was pleased with Praemium's performance during the second quarter. As a result, it appears increasingly confident that Praemium will report a solid half year result in February. Goldman has pencilled in sales of $24.5 million and underlying EBITDA of $6.9 million. This represents an 11% and 36% increase, respectively, over the prior corresponding period. I think Goldman makes some great points and Praemium could be worth considering.

ResMed Inc. (ASX: RMD)

A note out of Morgan Stanley reveals that its analysts have retained their overweight rating and lifted the price target on this sleep treatment company's shares to $24.30. According to the note, the broker believes the next round of changes to the reimbursement rate in the United States could boost its resupply revenue. It also feels that it is better positioned than many of its rivals to benefit from the changes. I agree with Morgan Stanley and would be a buyer of ResMed's shares with a long term view.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Praemium Limited. The Motley Fool Australia has recommended Praemium Limited and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »